Shares of drug firm Pfizer today trimmed most of its early gains and ended 3 per cent higher on emergence of profit-booking.
The stock which surged 7.15 per cent to Rs 1,785.80 in intra-day trade, later ended at Rs 1,712.45, up 2.75 per cent on BSE.
On NSE, shares of the company went up by 3 per cent to close at Rs 1,717.55.
The company is well placed to grow the Neksium brand further through its existing reach, coverage and equity in the gastrointestinal therapy area, Pfizer said in a statement yesterday.
Pfizer Ltd MD S Sridhar said: "The Neksium acquisition is aligned with our stated ambition of portfolio expansion through organic and inorganic growth in our focus therapy areas".
With this acquisition, the company will accelerate growth and strengthen its leadership position in the gastrointestinal (GI) therapy area, he added.
Disclaimer: No Business Standard Journalist was involved in creation of this content
